130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
Title:
130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
Author:
Ciruelos, E.M. Garcia, A.A. Cortés, J. Pernas Simon, S. Garate, E. Melé, M. Montaño, Á. Martinez-Jañez, N. Oliveira, M. Haba-Rodríguez, J. de la Vega, E. Martorell, A. Perello Bermejo De Las Heras, B. Cantos Sanchez De Ibarguen, B. Martínez, E. Navarro, E. Vila Pascual, T. González-Farré, X. Villagrasa, P. Prat, A.